A Glimpse into the PBAC December 2023 Meeting Outcomes

By Staff Writer

January 30, 2024

Introduction

The Pharmaceutical Benefits Advisory Committee (PBAC) concluded its December 2023 meeting with several key decisions that will shape the future of pharmaceutical treatments. Below we summarise these outcomes and highlight some potential future updates.

Noteworthy Decisions on Drug Listings

The PBAC meeting witnessed several crucial decisions on new drug listings and changes to existing ones. The recommendation list now includes Patisiran, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy.  This decision was based on the drug’s ability to delay disease progression and improve health-related quality of life. PBAC noted that in September 2023 it indicated that the economic model needed adjustments and that cost-effectiveness and financial figures were questionable. The sponsor’s updated proposal satisfied the economic model flaws.

Updates on Melatonin and Tyrosine Kinase Inhibitors

The PBAC revised its prior recommendation on using Melatonin to treat insomnia in Smith-Magenis syndrome (SMS) patients. They suggested that genetic testing could confirm SMS diagnosis and eliminate the need for a Risk Sharing Arrangement. Furthermore, they approved the restriction criteria for Tyrosine Kinase Inhibitors (TKIs). These include Asciminib, Dasatinib, Imatinib, Nilotinib, and Ponatinib, which are used to treat Chronic Myeloid Leukaemia (CML). The changes aim to align with current clinical practice.

Changes to Existing Drug Listings

The PBAC also recommended changes to the restriction levels of Upadacitinib, a drug used for treating severe active rheumatoid arthritis, from Authority Required (Written) to Authority Required (STREAMLINED). The committee noted that the market for Upadacitinib had stabilised and would not drive growth in the rheumatoid arthritis market.

Recommendations for Testing Methods

The committee also recommended changes to the restriction criteria for several drugs (including alectinib, brigatinib, and ceritinib) used in treating non-small cell lung cancer. These changes include the addition of next-generation sequencing gene panel testing as an eligible testing method for Pharmaceutical Benefits Scheme (PBS) subsidy in addition to fluorescence in situ hybridisation (FISH) testing.

Deferred Decisions

Not all decisions were finalised at the meeting. The PBAC deferred making a recommendation for an expanded listing of Nivolumab and Ipilimumab, as well as Pembrolizumab, for current or future Therapeutic Goods Administration (TGA) registration. These decisions were deferred to allow for further consultation with the sponsor and the Department.

Review of PBS Prescribing

The PBAC also reviewed the prescribing of PBS-listed medicines by nurse practitioners and endorsed midwives. The committee noted that a review is being undertaken by the Department on this matter, with an open consultation planned for early 2024. The PBAC and Department aim to collaborate with health professional groups to develop general principles for determining prescriber types for PBS listings.

Ultimately, the most recent PBAC list is lower in length when compared to the July 2023 list. It is important to note the numerous recommendations included. This indicates that Australia conducts ongoing, thorough evaluations. The aim is to ensure everyone has access to effective and affordable healthcare.

Reference url

Recent Posts

UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...

By Staff Writer

August 25, 2025

The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

By Staff Writer

August 21, 2025

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-lin...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Type 2 diabetes management in adults is undergoing significant changes with the draft 2025 NICE guideline update. What are the main improvements in medication, monitoring, and patient care for adults with type 2 diabetes? The answer: The new NICE recommendations prioritize a broader use of SGL...